Pascal Soriot (Getty)

As­traZeneca CEO So­ri­ot plans new study to test that con­tro­ver­sial 90% ef­fi­ca­cy fig­ure, wait­ing for US da­ta be­fore go­ing to FDA

Pas­cal So­ri­ot spent the long Thanks­giv­ing week­end dig­ging As­traZeneca out of a hole, promis­ing to put an end to the ques­tions around its in­ter­im Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.